Characterization of a 82Rb generator for positron emission tomography

Chudakov, V. M.; Жуйков, Б. Л.; Ermolaev, S. V.; Kokhanyuk, V. M.; Mostova, M. I.; Zaitsev, V. V.; Shatik, S. V.; Kostenikov, N. A.; Ryzhkova, D. V.; Tyutin, L. A.

doi:10.1134/s1066362214050142

Cited by 9 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…82 Rb‐generator GR‐01 with package design and 82 Rb elution system scheme is shown in Figure . The generator described in details in (Chudakov et al, ) consists of a generator column encased in a shielding container made of tungsten and steel (Figure a). The column contains a parent radionuclide 82 Sr (T 1/2 = 25.55 d) adsorbed on the ion‐exchange material based on hydrated tin oxide.…”

Section: Methodsmentioning

confidence: 99%

“…82 Rb-generator GR-01 with package design and 82 Rb elution system scheme is shown in Figure 1. The generator described in details in (Chudakov et al, 2014) consists of a generator column encased in a shielding container made of tungsten and steel ( Figure 1a).…”

Section: E Xperimentalmentioning

confidence: 99%

“…At present, the 82 Rb‐generators are mainly produced in the USA by GE Healthcare and distributed by Bracco Diagnostics Inc. (CardioGen ® ) (Bracco Diagnostics‐2000, 2000) (approved by FDA in 1989), as well as recently in Canada by Jubilant DraxImage (Ruby‐Fill ® ) (Jubilant DraxImage, ) (approved by FDA in 2016). The Russian 82 Rb generator GR‐01 which is produced and used at the clinic of the Russian Research Center of Radiology and Surgical Technologies of Ministry of Public Health (RRCRST, St. Petersburg) was developed in the Institute for Nuclear Research of Russian Academy of Sciences (INR, Moscow) with the participation of TRIUMF (Vancouver, Canada) (Chudakov et al, ; Chudakov, Zhuikov, & Ermolaev, ; Chudakov, Zhuikov, & Kokhanuk, ). A new approach of 82 Rb clinical application for PET 002Ddiagnostics in cardiology and later in oncology was developed in RRCRST in 2005–2007 (Granov, Matveev, Zhuikov, Kostenikov, & Rizhkova, ; Granov, Tyutin, & Kostenikov, ; Granov, Tyutin, Tlostanova, Rizhkova, & Kostenikov, ).…”

Section: Introductionmentioning

confidence: 99%

“…Generator for clinical use based on hydrated tin oxide were developed in the USA (Neidrickx, 1980), the UK (Waters, Horlock, & Kensett, 1983), Switzerland (Beyer, Rӧsch, & Ravn, 1990), Canada (Cackette, Ruth, & Vincent, 1993), Russia (Kodina, Kurenkov, Kurchatova, Malinin, & Yu, 1991;Litvinov et al, 1997), and Korea (Jeong et al, 1994). At present, the 82 Rb-generators are mainly (Chudakov et al, 2005(Chudakov et al, , 2014Chudakov, Zhuikov, & Kokhanuk, 2015). A new approach of 82 Rb clinical application for PET 002Ddiagnostics in cardiology and later in oncology was developed in RRCRST in 2005-2007(Granov, Matveev, Zhuikov, Kostenikov, & Rizhkova, 2011Granov, Tyutin, & Kostenikov, 2012;Granov, Tyutin, Tlostanova, Rizhkova, & Kostenikov, 1997).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Application of ⁸²Sr/⁸²Rb generator in neurooncology

et al. 2019

View full text Add to dashboard Cite

Introduction The applicability of “Rubidium Chloride, 82 Rb from Generator” radiopharmaceutical for brain tumors (BT) diagnostics is demonstrated on the basis of the application experience of the radiopharmaceutical in neurooncology. Experimental A total of 21 patients with various brain tumors and nonneoplastic abnormal brain masses were investigated. Results and Discussions The results of the imaging and differential diagnostics of malignant and benign tumors, nonneoplastic abnormal brain masses and lesions revealed the prevalence of high uptake of the radiopharmaceutical in the malignant tumors in comparison with benign glioma and arteriovenous malformations in which 82 Rb‐chloride accumulates in the vascular phase but does not linger further. The ultra‐short half‐life of radionuclide 82 Rb (76 s) along with a low absorbed radiation dose with 82 Rb‐chloride by intravenous administration create a new possibility of successive use of two or more radiopharmaceuticals for the examination of the same patient. For instance, PET examination with 18 F‐FDG, 11 C‐methionine, 11 C‐choline, or any other radiopharmaceutical can be carried out in just 7–15 min. after 82 Rb‐chloride injection. Conclusion Research demonstrated an effectiveness of 82 Rb‐chloride application as a diagnostic agent in neurooncology. A method of dosing and administration of the generator‐produced radiopharmaceutical has been worked out. It is possible to do up to 600 PET sessions using one Russian 82 Rb generator GR‐01. The generator is proved to be reliable and easy to use. The interest in 82 Rb‐chloride as a tumor‐seeking radiopharmaceutical rose due to the active application of the modern devices PET/CT in the routine clinical practice.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: E Xperimentalmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%